On April 21, 2025, Immunovant, a Roivant subsidiary, announced significant leadership changes and an expanded development plan for its lead asset, IMVT-1402. Eric Venker, M.D., Roivant’s President and an Immunovant Director, was appointed as Immunovant’s new CEO, succeeding Pete Salzmann, M.D., who retired. Renee Barnett also stepped down as CFO, with Tiago Girao taking over the role.
These leadership transitions are part of a strategic realignment as development activities for batoclimab conclude and focus shifts to IMVT-1402. The company also announced the expansion of IMVT-1402 development into two new indications: Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE). SjD is a chronic autoimmune disease with no approved therapies, while CLE is a rare chronic skin disease with high unmet need.
The Investigational New Drug (IND) application for CLE is now active, and a proof-of-concept trial evaluating IMVT-1402 has been initiated. These new indications broaden the potential market for IMVT-1402, which is positioned as a potentially best-in-class or first-in-class therapy. The changes reflect increased Roivant alignment and strategic oversight for Immunovant's future growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.